熱門資訊> 正文

Nasus Pharma 1H非GAAP每股收益为-0.54美元

2026-08-17 22:57

Nasus Pharma(NSRX) 0

Nasus Pharma Ltd. press release (NSRX): 1H Non-GAAP EPS of -$0.54.
Six months ended June 30, 2026, net loss totaled $5.94M.
Research and development expenses increased to $2.59M while general and administrative expenses rose to $3.45M.
Total cash, cash equivalents, and short-term deposits as of June 30, 2026, were $11.90M.

More on Nasus Pharma Ltd.

Seeking Alpha’s Quant Rating on Nasus Pharma Ltd.
Historical earnings data for Nasus Pharma Ltd.
Financial information for Nasus Pharma Ltd.

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。